Job-Oriented Training Programs at Azyme Biosciences
1. Diploma in Pharma
Biotechnology
Overview:
Our Diploma program prepares graduates and post graduates to excel in their technical fields, and to design, develop & implement strategies for dealing with challenges associated with those fields. The program’s primary focus is to prepare students to take up practical work in laboratories of food, biopharma, phytochemical, CROs and Govt. Laboratories.
Modules Covered:
1.Pharmaceutical
Microbiology
2. Recombinant DNA Technology
3.Immunological Techniques
4.Instrumentation- HPLC,GC,AAS & PCR
Duration: 3 months
2. Azyme Certified Quality Analyst (ACQA
Azyme Biosciences offers a unique and advanced training program on quality control. The ACQA program is an excellent program suitable for chemists, chemical engineers, microbiologists & biotechnologists, who plan to work in a quality control lab or upgrade their knowledge in the quality control sector.
Modules Covered:
1.Basic Techniques of Quality Analysis
2. Instrumentation-HPLC,GC & AAS
Duration– 45 days
Extensive Research Programs:
Objective:
The objective of the program is to familiarize students with the most modern techniques with a strong emphasis on understanding of basics. To imbibe fearless confidence in students to handle any experimental protocol.
Training Takeaways:
- Individual handling of all experimental protocols
- An understanding on the use & prepation of reagents and solutions
- Sample preparation and methods of analysis
- Result interpretation
- Troubleshooting techniques
Duration: 30-45 working days
Dissertation Projects
Project Topics Included but not limited to :
1.Molecular & Recombinant DNA technology
eg: DNA finger printing work , use of RAPD,RFLP,AFLP markers
2. Enzyme
Biotechnology
Eg; work currently being carried out industrially useful enzymes, enzymes with anti cancer activity
3. Phytochemical studies for antimicrobial activity
Eg: use of various plant parts for investigating their antimicrobial and antioxidant property.
4. Fermentation & downstream Processing / Industrial
Biotechnology
Eg : production of antibiotics, amino acids & enzymes
Duration: 45 days to 6 months
z7x2x3.initialize({
'userName':'jnuinterestforma',
'formHash':'z7x2x3',
'autoResize':true,
'height':'825',
'header':'show',
'ssl':true} ;
z7x2x3.display( ;
ADMISSION TO Ph.D PROGRAMME 2012
GURU GOBIND SINGH INDRAPRASTHA UNIVERSITY
DWARKA CAMPUS, SEC-16-C, NEW
Delhi
- 110 075
Applications are invited for admission to Ph.D Programme in various disciplines of Engineering, Management, Education, Medicine & Para Medical Health Sciences, Law & legal Studies, Humanities & Social Sciences and Applied Sciences in University School of Studies (USS and Approved Research Centres (ARC .
ELIGIBILITY CRITERIA :
An applicant possessing any one of the following qualifications shall be eligible to apply for admission to a Ph.D. programme of the University.
(i A Master’s degree in Technology/ Science/ Medicine/ Pharmacy/ Management/ of a recognized Indian University, or a post graduate degree approved by Association of Indian Universities/AICTE/ UGC/ MCI/ Bar Council/ Pharmacy Council, or any other equivalent qualification to the satisfaction of Academic Council of the University duly approved by equivalence committee of the University, in the relevant field, with not less than 60% marks in aggregate.
(ii (a Applicants with a Bachelor’s degree in Engineering/ Technology with either 75% or more marks in aggregate and a minimum of three years, or 60% or more marks in aggregate and a minimum of fifteen years, relevant experience in recognized Institute/ University/ Industry/ Government Organization, may be considered eligible for admission, on the recommendation of SRC and approval by BOS.
(ii (b Applicants with MBBS Degree (approved by MCI with either 60% or more marks in aggregate and a minimum of three years or 50% or more marks in aggregate and a minimum of 15 years relevant experience in Recognized Govt. Hospital/ Organization may be considered eligible for admission on the recommendation of SRC and approval by the BOS.
(iii For applicants belonging to SC/ST category and/or physically handicapped applicants, a relaxation of 5% in marks shall be admissible under eligibility conditions.
(iv Teachers working in any University or its affiliated colleges and having a teaching/research/other relevant experience of not less than 3 years may be allowed a relaxation of 5% marks under clause (i . Provided that out of the two relaxations stipulated under clauses (iii and (iv , only one relaxation is permissible for an applicant.
(v Perspective Research Candidate generally shall not have completed an age of 55 years at the time of submission of application for registration for Ph.D. A relaxation in the prescribed age beyond 55 years can, however be recommended by the SRC/BOS recording appropriate justification for the approval by the Vice-Chancellor.
SELECTION PROCEDURE : All the applicants shall have to appear for Research Aptitude Test (RAT except Foreign Nationals. Candidates shall be provisionally registered if they are selected through the entrance test RAT conducted by the G.G.S. Indraprastha University and thereafter Interview shall be conducted.
IMPORTANT DATES :
- Last date for receipt of applications : 16.04.2012 (Monday by 5:00(pm
- Date of written Test : 05.05.2012 (Saturday
The application form can be downloaded from the G.G.S. Indraprastha University Website:
http://www.ipu.ac.in in hyperlink Research & Consultancy. The interested candidates may apply by 16.04.2012 on the prescribed application form which is available on the University Website. Filled application form along with the relevant Certificates/ Testimonials must reach at “Director (Research & Consultancy office, Administrative Block, C-Wing, Room No. 005, Guru Gobind Singh Indraprastha University, Dwarka Campus, Sec-16 C, New
Delhi
-110 075.” Application received after due date will not be considered. There is no fee for filling the application form.
Deadline : 16.04.12
A multinational research team led by scientists at
Duke-NUS Graduate Medical School has identified the reason why some patients fail to respond to some of the most successful cancer drugs.
Tyrosine kinase inhibitor drugs (TKI work effectively in most patients to fight certain blood cell cancers, such as chronic myelogenous leukemia (CML , and non-small-cell lung cancers (NSCLC with mutations in the EGFR gene.
These precisely targeted drugs shut down molecular pathways that keep these cancers flourishing and include TKIs for treating CML, and the form of NSCLC with EGFR genetic mutations.
Now the team at Duke-NUS Graduate Medical School in Singapore, working with the
Genome Institute of Singapore (GIS ,
Singapore General Hospital, and the
National Cancer Centre Singapore, has discovered that there is a common variation in the BIM gene in people of East Asian descent that contributes to some patients' failure to benefit from these tyrosine kinase inhibitor drugs.
"Because we could determine in cells how the BIM gene variant caused TKI resistance, we were able to devise a strategy to overcome it," said
S. Tiong Ong, MBBCh, senior author of the study and associate professor in the Cancer and Stem Cell Biology Signature Research Programme at Duke-NUS and Division of Medical Oncology, Department of Medicine, at Duke University Medical Center.
"A novel class of drugs called the BH3-mimetics provided the answer," Ong said. "When the BH3 drugs were added to the TKI therapy in experiments conducted on cancer cells with the BIM gene variant, we were able to overcome the resistance conferred by the gene. Our next step will be to bring this to clinical trials with patients."
Said Yijun Ruan, PhD, a co-senior author of this study and associate director for Genome Technology and Biology at GIS: "We used a genome-wide sequencing approach to specifically look for structural changes in the DNA of patient samples. This helped in the discovery of the East Asian BIM gene variant. What's more gratifying is that this collaboration validates the use of basic genomic technology to make clinically important discoveries."
The study was published online in
Nature Medicine on March 18.
If the drug combination does override TKI resistance in people, this will be good news for those with the BIM gene variant, which occurs in about 15 percent of the typical East Asian population. By contrast, no people of European or African ancestry were found to have this gene variant.
"While it's interesting to learn about this ethnic difference for the mutation, the greater significance of the finding is that the same principle may apply for other populations," said
Patrick Casey, PhD, senior vice dean for research at Duke-NUS and James B. Duke Professor of Pharmacology and Cancer Biology.
"There may well be other, yet to be discovered gene variations that account for drug resistance in different world populations. These findings underscore the importance of learning all we can about cancer pathways, mutations, and treatments that work for different types of individuals. This is how we can personalize cancer treatment and, ultimately, control cancer."
"We estimate that about 14,000 newly diagnosed East Asian CML and EGFR non-small-cell lung cancer patients per year will carry the gene variant," Ong said. "Notably, EGFR NSCLC is much more common in East Asia, and accounts for about 50 percent of all non-small-cell lung cancers in East Asia, compared to only 10 percent in the West."
The researchers found that drug resistance occurred because of impaired production of BH3-containing forms of the BIM protein. They confirmed that restoring BIM gene function with the BH3 drugs worked to overcome TKI resistance in both types of cancer.
"BH3-mimetic drugs are already being studied in clinical trials in combination with chemotherapy, and we are hopeful that BH3 drugs in combination with TKIs can actually overcome this form of TKI resistance in patients with CML and EGFR non-small-cell lung cancer," Ong said. "We are working closely with GIS and the commercialization arm of the Agency for Science, Technology & Research (A*STAR , to develop a clinical test for the BIM gene variant, so that we can take our discovery quickly to the patient."
The major contributors to the study include additional researchers and teams from the Duke-NUS Graduate Medical School, Genome Institute of Singapore (Dr. Yijun Ruan and Dr. Axel Hillmer , Singapore General Hospital (Dr. Charles Chuah , and National Cancer Centre Singapore (Dr. Darren Wan-Teck Lim .
In addition, the investigators also received important contributions from Akita University Graduate School of Medicine, Japan (Dr. Naoto Takahashi , the Cancer Science Institute of Singapore (Dr. Ross Soo , the National University Cancer Institute of Singapore (Drs. Liang Piu Koh and Tan Min Chin , the Yong Loo Lin School of Medicine, National University of Singapore (Dr. Seet Ju Ee , the University of Bonn, Germany (Dr. Markus Nothen , the University of Malaya (Dr. Veera Nadarajan , and the University of Tokyo, Japan (Dr. Hiroyuki Mano .
The study was supported by grants from the National Medical Research Council (NMRC of Singapore; Biomedical Research Council (BMRC of A*STAR, Singapore; Genome Institute of Singapore; Singapore General Hospital; and two NMRC Clinician Scientist Awards to Dr. Ong and Dr Chuah.
“Human resistance to antibiotics could bring ‘the end of modern medicine as we know it’,” according to The Daily Telegraph. The newspaper says that we are facing an antibiotic crisis that could make routine operations impossible and a scratched knee potentially fatal. Similarly, the Daily Mail’s headline stated that a sore throat could soon become fatal.
The alarming headlines follow a new report by the World Health Organization (WHO , which set out ways to fight the growing problem of antimicrobial resistance (AMR . AMR occurs when infectious organisms, such as bacteria and viruses, adapt to treatments and become resistant to them. The publication specifically addressed the long-known problem of antibiotic resistance, where increasing use of antibiotics can lead to the formation of “superbugs” that resist many of the antibiotic types we currently have. It outlined a variety of measures that are vital for ensuring we can still fight infections in the future and described how other major infectious diseases, such as tuberculosis, HIV, malaria and influenza, could one day become resistant to today’s treatment options.
However, despite the future danger posed by antimicrobial resistance, the situation is not irretrievable. As Dr Margaret Chan, director general of WHO, said: “much can be done. This includes prescribing antibiotics appropriately and only when needed, following treatment correctly, restricting the use of antibiotics in food production to therapeutic purposes and tackling the problem of substandard and counterfeit medicines.” The report also highlighted successful cases where antimicrobial resistance has been tackled, demonstrating that we can safeguard the effectiveness of important antimicrobial medicines with dedicated, rational efforts.
Where has the news come from?
WHO has just published a new report (“The evolving threat of antimicrobial resistance - Options for action” that sets out a global strategy for fighting antibiotic resistance. It explores how over past decades, bacteria that cause common infections have gradually developed resistance to each new antibiotic developed, and how AMR has evolved to become a worldwide health threat. In particular, the report highlights that there is currently a lack of new antibiotics in development and outlines some of the measures needed to prevent a potential global crisis in healthcare.
This is not the first time WHO has set out such a strategy. In the 2001, WHO published its “Global strategy for containment of antimicrobial resistance”, which laid out a comprehensive list of recommendations for combating AMR. The current report looks at the experiences over the past decade of implementing some of these recommendations, the progress made, and what else should be done to tackle AMR.
What is antimicrobial resistance?
Antimicrobial resistance (AMR occurs when microorganisms, such as bacteria, viruses, fungi or other microbes, develop resistance to the drug that is being used to treat them. This means that the treatment no longer effectively kills or inactivates the microorganism. The term “antimicrobial” is used to describe all drugs that treat infections caused by microorganisms. Antibiotics are effective against bacteria only, antivirals against viruses, and antifungals against fungi.
The case of penicillin illustrates the AMR phenomenon well. When penicillin was first introduced in the 1940s, it revolutionised medicine and was effective against a wide range of staphylococcal and streptococcal bacteria. It was also able to treat infections that had previously been fatal for many people, including throat infections, pneumonia and wound infections. However, with increasing use of antibiotics over the decades, bacteria began to adapt and develop changes in their DNA that meant they were resistant to the actions of the once powerful antibiotic. These bacteria would survive and proliferate, which meant their protective genes would then be passed on to other strains of bacteria. As a result, new and stronger antibiotics had to be created to combat the resistant bacteria.
AMR is driven by many factors, including overuse of antimicrobials for human and animal health and in food production, which can allow microbes to adapt to antimicrobials they are exposed to. Poor infection-control measures, which fail to prevent the spread of infections, also contribute. In particular, the WHO publication reports what it describes as the five most important areas for the control of AMR, as recognised in its 2001 strategy:
- surveillance of antimicrobial use
- rational use in humans
- rational use in animals
- infection prevention and control
- innovations in practice and new antimicrobials
How big is the problem?
As the report describes, AMR makes it difficult and more expensive to treat many common infections, causing delays in effective treatment or, in the worst cases, an inability to provide effective treatment at all. Many patients around the world suffer harm because infections from bacteria, viruses, fungi or other organisms can no longer be treated with the common medicines that would once have treated them effectively.
The report presents some startling facts on major infectious diseases worldwide:
- Malaria: malaria is caused by parasites that are transmitted into the bloodstream by a bite from an infected mosquito. Resistance to antimalarial medicines has been documented for all classes of the drug, which presents a major threat to malaria control. The report describes that a change in national antimalarial treatment policy is recommended when the overall treatment failure rate exceeds 10%. Changes in policy have been necessary in many countries due to the emergence of chloroquine resistance. This means that alternative forms of combination therapy have to be used as first-line treatment.
- Tuberculosis: in 2010, an estimated 290,000 new multidrug-resistant tuberculosis (TB cases were detected among the TB cases notified worldwide, and about one-third of these patients may die annually. Inaccuracies in diagnosis also impede appropriate treatment.
- HIV: resistance rates to anti-HIV drug regimens ranging from 10% to 20% have been reported in Europe and the USA. Second-line treatments are generally effective in patients when the first-line therapy has failed, but can only be started promptly if viral monitoring is routinely available.
- Common bacterial infections: various bacteria can cause infections within the chest, skin and urinary tract bloodstream, for example, and the inability to fight these infections appears to a growing problem in healthcare. Estimates from Europe are that there are 25,000 excess deaths each year due to resistant bacterial hospital infections, and approximately 2.5 million avoidable days in hospital caused by AMR. In addition, the economic burden from additional patient illness and death is estimated to be at least ˆ1.5 billion each year in healthcare costs and productivity losses.
What can be done about AMR?
The five key areas that the report highlights could tackle the problem of AMR are as follows:
Surveillance of antimicrobial use
Tracking antimicrobial use (in particular antibiotic use and looking at the emergence and spread of resistant strains of bacteria is a key tactic in the fight against AMR. This can provide information, insights and tools needed to guide policy and measure how successful changes in prescribing may be. This can happen both locally and globally.
AMR is a global problem but, at present, there appears to be wide variation in the way regions and countries approach AMR surveillance. This means there is a long way to go before it can be carried out worldwide.
Rational use in humans
Antimicrobials can obviously be important or even lifesaving in appropriate situations, but it is just as important to prevent unnecessary use of antimicrobials, which can lead to resistance. Putting this into practice worldwide is said to be difficult, but rationalising antimicrobial use has had a demonstrable impact on AMR in some cases.
Rational use in animals
Antibiotics are said to be used in greater quantities in food production than in the treatment of disease in human patients. Also, some of the same antibiotics or classes are used in animals and in human medicine. This carries the risk of the emergence and spread of resistant bacteria, including those capable of causing infections in both animals and people.
The problems associated with the use of antibiotics in animal husbandry, including in livestock, poultry and fish farming, are reportedly growing worldwide without clear evidence of the need for or benefit from it. There are said to be major differences in the amounts of antimicrobials used per kilogram of meat produced in high-income countries, and actions need to be taken by national and international authorities to control this.
Infection prevention and control in healthcare facilities
The hospital environment favours the emergence and spread of resistant bacteria. The report highlights the importance of infection-control measures to prevent the spread of microbes in general, regardless of whether they are resistant to antimicrobials. Many facilities and countries are reported to have progressed well since 2001, implementing many recommendations on infection control and prevention, although gaps and challenges still remain.
Innovations
Lastly, the report describes how innovative strategies and technologies are needed to address the lack of new antimicrobials being produced. As the report says, while antimicrobials are the mainstay of treatment for infections, diagnostics and vaccines play important complementary roles by promoting rational use of such medicines and preventing infections that would require antimicrobial treatment. So far, new products coming on to the market have not kept pace with the increasing needs for improvements in antimicrobial treatment. However, current challenges to new research developments can be both scientific and financial.
Can these strategies really stop AMR?
While AMR poses a significant threat to health in the future, the situation does not appear to be irretrievable. The WHO report and an accompanying press release highlight some examples of success stories over the past years:
- In Thailand, the "Antibiotic Smart Use" programme is reported to have reduced both the prescribing of antibiotics by prescribers and the demand for them by patients. It demonstrated an 18–46% decrease in antibiotic use, while 97% of targeted patients were reported to have recovered or improved regardless of whether they had taken antibiotics.
- A pharmacy programme in Vietnam reportedly consisted of inspection of prescription-only drugs, education on pharmacy treatment guidelines and group meetings of pharmacy staff. These measures were reported to give significant reduction in antibiotic dispensing for acute respiratory infections.
- In Norway, the introduction of effective vaccines in farmed salmon and trout, together with improved fish health management, was reported to have reduced the annual use of antimicrobials in farmed fish by 98% between 1987 and 2004.
- In 2010, the University of Zambia School of Medicine was reported to have revised its undergraduate medical curriculum. AMR and rational use of medicines were made key new topics to ensure that graduates who enter clinical practice have the right skills and attitudes to be both effective practitioners and take a role in fighting AMR.
How can I help?
There are times when antibiotics are necessary or even vital. However, as patients and consumers, it is important to remember that antibiotics or other antimicrobials are not always needed to treat our illnesses, and we should not expect them in every situation.
For example, the common cold is caused by a virus, which means it does not respond to antibiotics. However, people may expect to be given antibiotics by their doctor when they are affected, even though they offer no direct benefit and could raise the risk of bacteria becoming resistant. Furthermore many common viral and bacterial infections such as coughs, throat and ear infections and stomach upsets, are “self-limiting” in healthy people, which means they will generally get better with no treatment at all.
If, on the other hand, you are prescribed an antimicrobial, it is important to take the full course as directed. Taking only a partial course of an antimicrobial may not kill the organism but may expose it to a low dose of a drug which can then contribute to resistance.
Links To The Headlines
Health chief warns: age of safe medicine is ending. The Independent, March 16 2012
Resistance to antibiotics could bring "the end of modern medicine as we know it", WHO claim. The Daily Telegraph, March 16 2012
Why a sore throat could soon be fatal: Bugs are becoming more resistant to antibiotics, warn health chiefs. Daily Mail, March 16 2012
Links To Science
WHO: The evolving threat of antimicrobial resistance - Options for action. March 16 2012
A walk-in- interview will be conducted on March 26, 2012 at 11:15 AM in the department of
Biotechnology
, Indian Institute of Technology, Roorkee to select candidates for the following position as per details given below under the
DBT
sponsored research scheme, "Environmental chemicals and their impact on thyroid functions: An in vitro and in vivo approach to identify them and understand their mode of action" under Dr. Partha Roy, P.I & Associate Professor, Department of
Biotechnology
, Indian Institute of Technology Roorkee, for a period up to two years:
Post :
Junior Research Fellow
(One
Fellowship : Rs. 12,000/- PM for first two years and Rs. 14,000/- PM third year
Eligiblity :
1.
M.Sc
in
Biotechnology
/
Biochemistry
/
Life Science
/ M.PharmaJ M.VSc./
M.Tech
(
Biotechnology
/ M.E. (
Biotechnology
2.Candidates should be qualified UGC-
CSIR
-
JRF
/ Lectureship or GATE.
Age : 28 Years, relaxable up to 5 years in the case of candidates belonging to scheduled castes/ tribes and three years in the case of OBC; woman and physically handicapped candidates as per rules.
Application should be Indian national and he/she should bring an application on plain paper giving full details of educational qualifications along with their attested copies while attending the interview. No TA/DA will be paid to the candidate for attending this interview. All terms and conditions are as per rules of lIT Roorkee and
DBT
.
Walk in Interview : 26.03.12
